Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biomira and Prima BioMed's anticancer candidate CVac has generated positive results in an ongoing phase IIa clinical trial in ovarian cancer.
Subscribe to our email newsletter
Analysis of data from the trial indicates that, so far, 21% of patients in the trial have achieved either a clinical response to treatment or stabilization of their disease. Patients in the overall study are late-stage progressive ovarian cancer patients with no therapeutic alternative.
The primary objective of the trial is to determine whether CVac, a cancer immunotherapy, can produce clinical responses or stabilization of ovarian cancer, as determined by monitoring the blood marker CA125, a well recognized tumor marker of disease activity.
The trial recruited 28 ovarian cancer patients, all of whom had previously failed other forms of therapy and were assessed as having progressive disease by increases in CA125 levels. Of these patients, 21 went on to complete the requisite dosing (three injections) of CVac to qualify for inclusion in the study.